AU4848293A - Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection - Google Patents

Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Info

Publication number
AU4848293A
AU4848293A AU48482/93A AU4848293A AU4848293A AU 4848293 A AU4848293 A AU 4848293A AU 48482/93 A AU48482/93 A AU 48482/93A AU 4848293 A AU4848293 A AU 4848293A AU 4848293 A AU4848293 A AU 4848293A
Authority
AU
Australia
Prior art keywords
hiv
methyl
treatment drug
amino
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48482/93A
Other languages
English (en)
Inventor
Donald Herman M. D Batts
Thomas Jerome Dueweke
William Gary Tarpley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU4848293A publication Critical patent/AU4848293A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU48482/93A 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection Abandoned AU4848293A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US967639 1992-10-28
US1711993A 1993-02-12 1993-02-12
US017119 1993-02-12
PCT/US1993/008354 WO1994009781A1 (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Publications (1)

Publication Number Publication Date
AU4848293A true AU4848293A (en) 1994-05-24

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48482/93A Abandoned AU4848293A (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Country Status (12)

Country Link
EP (1) EP0666744A1 (fi)
JP (1) JPH08502745A (fi)
KR (1) KR950703958A (fi)
AU (1) AU4848293A (fi)
CA (1) CA2145545A1 (fi)
CZ (1) CZ69695A3 (fi)
FI (1) FI952018A (fi)
HU (1) HUT72050A (fi)
MX (1) MX9306031A (fi)
NO (1) NO951608L (fi)
PL (1) PL308551A1 (fi)
WO (1) WO1994009781A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
WO2004022060A2 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
EP0666744A1 (en) 1995-08-16
CZ69695A3 (en) 1995-12-13
WO1994009781A1 (en) 1994-05-11
MX9306031A (es) 1994-04-29
PL308551A1 (en) 1995-08-21
FI952018A0 (fi) 1995-04-27
FI952018A (fi) 1995-04-27
CA2145545A1 (en) 1994-05-11
KR950703958A (ko) 1995-11-17
JPH08502745A (ja) 1996-03-26
NO951608D0 (no) 1995-04-27
HUT72050A (en) 1996-03-28
HU9501218D0 (en) 1995-06-28
NO951608L (no) 1995-06-28

Similar Documents

Publication Publication Date Title
JP7113009B2 (ja) 置換ピリジノン含有三環式化合物およびそれを使用する方法
RU2478387C2 (ru) ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
ES2312568T3 (es) Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
AU2012246490B2 (en) Therapeutic agent for tumor
DK2799070T3 (en) EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS
US20090062301A1 (en) Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one ja k3 kinase inhibitor for treating autoimmune disorders
CN104144913A (zh) B型肝炎抗病毒剂
JP6795518B2 (ja) キナーゼを阻害する組成物及び方法
JP2818299B2 (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
BR112020019134A2 (pt) produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos
WO2012161301A1 (ja) ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
AU4848293A (en) Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection
WO2013071693A1 (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
JP4610481B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
ES2215327T3 (es) Composicion de medicamento inmunomodulador.
WO2022033460A1 (zh) Btk抑制剂治疗疾病的用途
JP2002293745A (ja) 慢性関節リウマチ治療剤
CN109875999B (zh) 泊那替尼在kit突变型恶性黑色素瘤中的应用
CA2250844C (en) Anti-hiv composition comprising imidazole derivatives
EP1667719A1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
BRPI0617074A2 (pt) composição farmacêutica, uso de lamivudina, nevirapina e stavudina, uso de stavudina, lamivudina e nevirapina, método para tratar uma infecção viral em um humano, método para preparar uma composição farmacêutica, método para preparar uma forma de dosagem unitária farmacêutica bicamadas e método para preparar uma forma de dosagem unitária farmacêutica tri-camadas
AU2003296872A1 (en) Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
WO2019071105A1 (en) CRYSTALLINE COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS